Pharmacological Management of Disinhibition in Elderly Patients with Delirium and Possible Dementia

Current Situation Assessment

A 68-year-old male patient with protracted delirium, disinhibition, and possible underlying dementia has experienced extrapyramidal side effects with haloperidol and thrombocytopenia with sodium valproate, making quetiapine the most appropriate pharmacological option given his minimal response to olanzapine, according to the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines 1
The patient presents with a complex clinical picture of protracted delirium with pronounced disinhibition that could represent behavioral and psychological symptoms of dementia (BPSD) 1

Quetiapine may offer benefit in the symptomatic management of delirium according to ESMO Clinical Practice Guidelines, with a lower risk of extrapyramidal side effects compared to first-generation antipsychotics like haloperidol 1
Short-acting antipsychotics like quetiapine showed statistically significant improvement at day 7 of treatment in delirium patients, as recommended by the European Society for Medical Oncology (ESMO) 2
Aripiprazole may offer benefit in symptomatic management of delirium, with fewer adverse events compared to haloperidol, risperidone, and olanzapine, according to the American Society of Clinical Oncology (ASCO) 2
Methylphenidate may improve cognition in hypoactive delirium where delusions and perceptual disturbances are absent, with demonstrated cognitive improvement in all patients in one study, as reported by the National Comprehensive Cancer Network (NCCN) 2
Opioid rotation, such as switching to fentanyl or methadone, is an efficacious strategy for opioid-associated delirium, with studies showing 80-90% response rates, according to the World Health Organization (WHO) 2

Pharmacological interventions should be limited to patients with distressing symptoms or safety concerns, and medications should be used at the lowest effective dose and for the shortest period possible, as recommended by the European Society for Medical Oncology (ESMO) 1
Avoid combining multiple antipsychotics due to increased risk of adverse effects without clear additional benefit, according to the American Society of Clinical Oncology (ASCO) 3
Monitor for sedation, extrapyramidal symptoms, QT prolongation, and cognitive function, as recommended by the National Comprehensive Cancer Network (NCCN) 4

Identify and address possible causes of delirium, including drug-induced delirium, and optimize pain control before implementing pharmacological approaches, as recommended by the World Health Organization (WHO) 6
Use standardized assessment tools like CAM-ICU or ICDSC to evaluate delirium, according to the European Society for Medical Oncology (ESMO) 6